Early-stage academic research compound; no IND filed, no human trials conducted as of the studies reviewed.
SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptor subfamily (ERR-alpha, ERR-beta, ERR-gamma), most potent at ERR-alpha. Activation of these nuclear receptors induces transcription...
SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptor subfamily (ERR-alpha, ERR-beta, ERR-gamma), most potent at ERR-alpha. Activation of these nuclear receptors induces transcriptional programs governing mitochondrial biogenesis, oxidative muscle fiber type, and fatty-acid utilization, and it has been studied as a pharmacological "exercise mimetic" tool for aerobic-metabolism research, including a cardioprotective effect in a mouse heart-failure model.
Circulation · 2024
SLU-PP-332 and a related analogue improved ejection fraction, reduced fibrosis, and increased survival in a mouse pressure-overload heart failure model.
View Source →ACS Chemical Biology · 2023
The original characterization paper: SLU-PP-332 increased mitochondrial respiration in skeletal muscle cells and increased oxidative muscle fiber content and exercise endurance in mice via an ERRα-dependent gene program.
View Source →